Clinical trial
Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With…
NCT00189579 · ARCAGY/ GINECO GROUP, Other · Terminated
Key facts
| NCT number | NCT00189579 |
|---|---|
| Title | Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer |
| Official title | A Phase II Study Designed to Evaluate the Safety and Efficacy of the Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Early Relapse Patients (< 6 Months) With Ovarian Cancer, Overexpressing HER2, Previously Treated With Carboplatin-Paclitaxel |
| Lead sponsor | ARCAGY/ GINECO GROUP, Other |
| Collaborators | Hoffmann-La Roche Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | Herceptin |
| Enrollment | 45 |
| Completion | Jan 1, 2007 |
| First posted | Sep 19, 2005 |
| Last update posted | Aug 17, 2007 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: